In a blockbuster pharma merger that shook the global biotech sector, Sanofi announced Friday it has officially completed its acquisition of U.S.-based Blueprint Medicines Corp., closing a deal worth up to $9.5 billion and sending a clear message that it’s doubling down on its rare disease and immunology bets.
The French pharmaceutical titan, advised by Weil Gotshal & Manges LLP, confirmed that all conditions of the tender offer have been satisfied, and it will now move swiftly to pay shareholders who validly tendered their shares. The acquisition prompted the delisting of Blueprint’s stock from the Nasdaq Global Select Market, marking the end of the U.S. biotech’s run as a publicly traded entity.
A Strategic Leap in Rare Disease and Immunology
Originally announced in June, the deal is not just about market consolidation—it’s about pipeline power. With Blueprint, Sanofi inherits a suite of next-generation treatments that could redefine standards in rare disease therapies, including Ayvakit and Blu-808.
Ayvakit, a standout treatment targeting systemic mastocytosis and other rare disorders, raked in $479 million in net revenue in 2024, followed by an impressive $150 million haul in Q1 2025 alone. That kind of trajectory made Blueprint a prized target in the fiercely competitive biotech M&A arena.
Sanofi sees the acquisition as a major boost to its immunology portfolio, with potential synergies in research, development, and global commercialization.
